Dr. Jeffrey Michael Kamradt, MD

Dr. Kamradt practices at Hartford Hospital in Hartford, Connecticut, part of Hartford HealthCare.

Dr. Kamradt's NPI, 1912949165, was assigned on June 12, 2006. Dr. Kamradt graduated from Indiana University School Of Medicine in 1993. Dr. Kamradt holds Connecticut license 037516.

Dr. Kamradt's primary practice is Hartford Hospital, at 80 Seymour Street, Hartford, CT 06102 in Hartford County. The practice phone is (860) 545-5000.

Dr. Kamradt's primary practice is Hartford Hospital in Hartford, Connecticut, part of Hartford HealthCare. Dr. Kamradt is also affiliated with The Hospital of Central Connecticut. The medical group on file is Hartford Hospital. Dmand AI also links Dr. Kamradt to 3 more hospitals, 4 medical groups, 2 group practices and clinics and 1 hospice, each named with a free account. Dr. Kamradt's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kamradt practices, 8 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Kamradt's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Kamradt is licensed in Connecticut.

CMS data shows 719 Medicare services from Dr. Kamradt across 5 procedure codes in 2024, for 269 Medicare patients. Medicare paid $55,656 for them.

CMS counts 269 Medicare patients who saw Dr. Kamradt in 2024. The largest group is 75 to 84, with 113 patients. 75% of them have cancer, and 75% have high blood pressure. 12% are also on Medicaid. Their average risk score is 2.31, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kamradt's median patient age at 74, with 16% women.

In 2024, Dr. Kamradt wrote 1,962 Medicare Part D claims for 216 patients. 73% of them were for generic drugs. CMS names the drug for 1,729 of them, across 27 drugs with 11 or more claims each, at $6,077,166 in total drug cost. In 2023, CMS named 1,585 claims across 33 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Kamradt for performance year 2024, reported as part of a group. Dr. Kamradt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kamradt as offering telehealth.

Dmand AI links 4 papers to Dr. Kamradt, published from 2020 to 2023. The most frequent topics are Cisplatin, Gemcitabine and Neoadjuvant Therapy. Dr. Kamradt has published most often in J Clin Oncol. Dr. Kamradt's most frequent co-authors are Dean F. Bajorin, MD, Bernard H. Bochner, MD and Eugene K. Cha, MD.

Dmand AI links Dr. Kamradt to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Carcinoma, Renal Cell, Carcinoma, Transitional Cell and Kidney Neoplasms.

CMS Open Payments shows 10 general payments to Dr. Kamradt from 6 drug and device companies from 2017 to 2022. Education make up the largest share, 73% of the total. Seagen Inc. paid the most, $49.

Dr. Kamradt graduated from Indiana University School Of Medicine in 1993.